ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Positive CHMP opinion for finerenone as new treatment for chronic kidney disease and type 2 diabetes
December 20, 2021It is estimated that chronic kidney disease affects more than 160 million people with type 2 diabetes worldwide. -
Bayer announces FDA accepts NDA and grants priority review for Finerenone for patients with CKD and T2D
January 18, 2021Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted Priority Review for finerenone, an investigational drug for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Pharma Sources Insight January 2025
